ClinicalTrials.gg
Status unknownNCT05246982Updated May 2, 2022

HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer

A Phase 2 interventional study of HLX07+HLX10+oxaliplatin+capecitabine and HLX07 in Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ), sponsored by Shanghai Henlius Biotech. Status unknown at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-02.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing serplulimab in Stomach Neoplasms — 8 open to participants now, 11 under way, none of them phase 3. serplulimab · Stomach Neoplasms.

Planned enrollment
12th of 14
40 · median 59
Started
2022
with 2 others
Phase 2
13 of 14
8 open now
Registered
2nd of 14
by date
Lead sponsor
2 of 14
Shanghai Henlius Biotech

Among the 14 studies testing serplulimab in Stomach Neoplasms, this one is the 12th largest by planned enrollment, is one of 3 that started in 2022, is one of 13 in phase 2, and was the 2nd registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

8 of the 14 studies testing serplulimab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About serplulimab

serplulimab: first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing serplulimab in Stomach Neoplasms, or all of them as a file.
02

Study summary

This study is conducted in patients with advanced metastatic gastric cancer including gastroesophageal junction cancer. This study includes two arms: A and B. Arm A (patients with HER2 negative and PD-L1 CPS≥5 ) will receive HLX07 combination therapy with HLX10 and chemotherapy (oxaliplatin+capecitabine) as first-line treatment. Arm B will receive HLX07 monotherapy as third-line or above treatment. All of eligible patients will receive study drug treatment until loss of clinical benefit, unacceptable toxicity, death, withdrawal of informed consent (whichever occurs first, HLX10 treatment up to 2 years).

03

Conditions studied

  • Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteer to participate in this clinical study; completely understand and know this study as well as sign the form (ICF); be willing to follow and be able to complete all study procedures;
  2. Age ≥ 18 years and ≤ 75 years when ICF is signed;
  3. Unresectable locally advanced, or gastric cancer including gastroesophageal junction cancer, and histopathologically confirmed diagnosis of adenocarcinoma;
  4. Arm A: never received systemic anti-tumor drug therapy before, with negative and CPS≥5; Arm B: failed to prior systemic anti-tumor therapy (at least 2 lines);
  5. according to v1.1 by IRRC;
  6. score 0-1;
  7. Expected survival 12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Has other active within 5 years before the first administration of the study drug;
  2. Plan to or have previously received organ or bone marrow transplantation;
  3. Uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated drainage;
  4. Arm A: previously received antibody drugs against immune checkpoints (such as , PD-L1, CTLA4, etc.) and / or antibody drugs against EGFR; Arm B: previously received antibody drug treatment against EGFR;
  5. Have received any research drugs within 14 days before the first use of the study drugs.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Arm A

    HER2 negative and PD-L1 CPS≥5, as first-line therapy

    Drug: HLX07+HLX10+oxaliplatin+capecitabine

  • Experimental
    Arm B

    As third-line or above therapy

    Drug: HLX07

Interventions

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate by IRRC assessment per RECIST 1.1

    Time frame: Up to 2 years

  2. PFS

    Progression-free survival by IRRC assessment per RECIST 1.1

    Time frame: From the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier), assessed up to 2 years

Secondary outcomes

  1. OS

    Overall survival

    Time frame: From the date of first dose unitl the date of death from any cause,assessed up to 2 years

  2. ORR

    Objective response rate by INV assessment per RECIST 1.1

    Time frame: Up to 2 years

  3. PFS

    Objective response rate by INV assessment per RECIST 1.1

    Time frame: From the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier), assessed up to 2 years

  4. DOR

    Duration of response by IRRC/INV assessment per RECIST 1.1

    Time frame: From the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier),assessed up to 2 years

07

Study locations

2 of 2 sites recruiting
  • Gansu Wuwei Tumor Hospital
    Wuwei, Gansu 730000, China
    Recruiting
  • Fudan University shanghai cancer center
    Shanghai, 200000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2023, 20 months after the start.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's planned 20 months is below that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2022
First posted
Feb 18, 2022
StartActual
Mar 23, 2022
Primary completionEst.
Dec 20, 2023
CompletionEst.
Mar 30, 2024
Last update
May 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05246982
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Mar 23, 2022
Primary completion
Dec 20, 2023 (estimated)
Completion
Mar 30, 2024 (estimated)
Last update
May 2, 2022

Study contacts

Dazhi Xu, MD
Contact
xudzh@shca.org.cn
021-64175590

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HLX07 · Serplulimab · Oxaliplatin · Capecitabine

Start the discussion